NCT06725693 Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
| NCT ID | NCT06725693 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University |
| Condition | GLP1-R-related Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2019-02-01 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2019-02-01 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.
Eligibility Criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06725693 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying GLP1-R-related Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06725693 currently recruiting?
Yes, NCT06725693 is actively recruiting participants. Contact the research team at qs_c8@hotmail.com for enrollment information.
Where is the NCT06725693 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06725693 clinical trial?
NCT06725693 is sponsored by Tianjin Medical University. The trial plans to enroll 500 participants.